ovarian cancer

Make a delay and accumulation of outstanding tasks Full stop
Biotech

Accent halts DHX9 inhibitor trial over adverse events

Accent Therapeutics has halted work on a solid tumor drug due to adverse events in a phase 1/2 study.
James Waldron Feb 26, 2026 5:01am
pause halt pause button

FDA freezes enrollment in MacroGenics cancer trial after death

Feb 24, 2026 2:00pm
On target clinical trial success bullseye score

Corcept racks up ph. 3 cancer win to bounce back from FDA blow

Jan 22, 2026 9:45am
An arrow incrementally going up stairs before pointing straight up Blue background

ESMO: Daiichi, Merck move ovarian cancer ADC toward pivotal test

Oct 20, 2025 10:45am
Cancer mutation precision medicine oncology targeted

ESMO: Tubulis' next-gen ADC lives up to hype with 59% ORR

Oct 19, 2025 4:15am
RD oil pipeline

Genmab discards ADC from $1.8B ProfoundBio buy

Sep 16, 2025 10:33am